Remarks

I. Restriction Requirement

In the above referenced Office Action, the Examiner divided the claims into the following groups:

Group I. Claims 1-10, drawn to methods for regenerating nerves, classified in class 514, subclass 12 or 44, for example; and

Group II. Claims 21-30, drawn to compositions, classified in class 514, subclass 12 or 44, for example.

In response, Applicants elect to begin prosecution with examination of claim group II, claims 21-30, without traverse. Non-elected claims 1-10 are cancelled.

Applicants reserve the right to file a divisional application directed to the non-elected claims of Group I.

II. Species Proposed By The Examiner

In the above-referenced Office action, the Examiner further divided the claims into the following species:

Species a: MAG;

Species b: GT1b;

Species c: p75;

Species d: Rho GD1;

Species e: Rho;

Species f: p21;

Species g: Rho kinase;

Species h: a Pep5 polypeptide;

Species i: a nucleic acid encoding a Pep5 polypeptide;

Species j: a p75 extracellular domain polypeptide;

Species k: a nucleic acid encoding a p75 extracellular domain polypeptide;

Species l: the Rho GDI polypeptide;

Species m: a nucleic acid encoding the Rho GDI polypeptide;

Species n: a p21 polypeptide;

Species o: a nucleic acid encoding a p21 polypeptide;

Species p: PKC; and

Species q: IP3.

In response, Applicants elect species h, a Pep5 polypeptide, without traverse.

It is Applicants' understanding that remaining pending claims 21-23 and 25-31 read on elected species h. With regard to claims 25-26, and 29, it is Applicants' understanding that the functional recitations:

(i) inhibition of an interaction between p75 and Rho, (ii) inhibition of an interaction between p75 and Rho GDI, (iii) maintenance or enhancement of an interaction between Rho and Rho GDI, (iv) inhibition of conversion from Rho GDP to Rho GTP, (v) inhibition of an interaction between Rho and Rho kinase, and (vi) inhibition of an activity of Rho kinase of claim 25;

(i) an agent capable of suppressing or extinguishing an interaction between p75 and Rho GDI, (ii) an agent capable of suppressing or extinguishing an interaction between p75 and Rho, (iii) an agent capable of maintaining or enhancing an interaction between Rho and Rho GDI, (iv) an agent capable of inhibiting conversion from Rho GDP to Rho GTP, (v) an agent capable of inhibiting an interaction between Rho and Rho kinase, and (vi) an agent capable of inhibiting an activity of Rho kinase of claim 26; and

(i) an agent capable of specifically interacting with a p75 polypeptide (ii) an agent capable of specifically interacting with a Rho GDI polypeptide, (iii) an agent capable of specifically interacting with a Rho polypeptide, and (iv) an agent capable of specifically interacting with a Rho kinase of claim 29 read on elected species h.

Applicants make no representation as to whether or not the remaining functional limitations read on the elected species at this time. Applicants further reserve the right to make such a statement at a later date if necessary.

Upon allowance of the generic claims, Applicants request consideration of claims to additional species which are written in dependent form or which otherwise include all the limitations of the allowed generic claim(s) as provided by 37 C.F.R. §1.141.

II. <u>Amendments</u>

Non-elected claims 1-10 stand cancelled.

Claim 24 is withdrawn. Upon allowance of the generic claims, Applicants request consideration of claims to additional species which are written in dependent form or which otherwise include all the limitations of the allowed generic claim(s) as provided by 37 C.F.R. §1.141.

No new matter is added by way of these amendments.

If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is encouraged to call the undersigned at (650) 838-4410.

Respectfully submitted,

Jacqueline F. Mahoney
Registration No. 48,390

Date: July 25, 2005

<u>Correspondence Address:</u>
Customer No. 22918
(650) 838-4410